Cargando…

Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients

BACKGROUND: Since the introduction of direct antiviral agents (DAAs), morbidity of HCV has considerably decreased but still no guidelines have been formulated in renal transplant recipients (RTRs). We studied efficacy and tolerability of direct antiviral agents in RTRs. METHODS: This prospective obs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Sourabh, Mukherjee, Debabrata, Nair, Ranjith K., Datt, Bhaskar, Rao, Ananth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896212/ https://www.ncbi.nlm.nih.gov/pubmed/29796311 http://dx.doi.org/10.1155/2018/7579689

Ejemplares similares

The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients
por: Gottlieb, Robert L., et al.
Publicado: (2018)

Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study
por: Chen, Keliang, et al.
Publicado: (2017)

Use of direct antiviral agents in liver transplant recipients with hepatitis C virus in Korea: 2-center experience
por: Kim, Jong Man, et al.
Publicado: (2018)

Hepatitis C and renal transplantation in era of new antiviral agents
por: Salvadori, Maurizio, et al.
Publicado: (2018)

Direct-acting Antiviral Agents in Hepatitis C Virus-infected Renal Allograft Recipients: Treatment and Outcome Experience from Single Center
por: Prasad, N., et al.
Publicado: (2018)

Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates
por: Gadiparthi, Chiranjeevi, et al.
Publicado: (2018)

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection
por: Lin, Ming V., et al.
Publicado: (2016)

Direct‐acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta‐analysis
por: Liu, Jiaye, et al.
Publicado: (2019)

Corrigendum: Direct-acting antiviral agents in Hepatitis C Virus infected renal allograft recipients: Treatment and outcome experience from single center
Publicado: (2018)

Successful Antiviral Treatment with Direct-Acting Antivirals for Hepatitis C Virus Infection during Peritransplant Period in a Kidney Transplant Recipient
por: Varotti, Giovanni, et al.
Publicado: (2021)

Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus
por: Tavares, Rita Chelly Felix, et al.
Publicado: (2018)

Efficacy and safety of new direct-acting antivirals in kidney transplant recipients with chronic hepatitis C: a single-center study
por: Darema, Maria, et al.
Publicado: (2020)

Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus
por: Rupp, Christian, et al.
Publicado: (2018)

Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]
Publicado: (2018)

Changing Population of Liver Transplant Recipients in the Era of Direct-acting Antiviral Therapy
por: Xie, Chencheng, et al.
Publicado: (2020)

Hepatitis E Infection in a Renal Transplant Recipient
por: Vassallo, Diana, et al.
Publicado: (2014)

Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience
por: Alkadi, Mohamad M., et al.
Publicado: (2020)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
por: Armando, Calogero, et al.
Publicado: (2019)

A safety and efficacy analysis of direct-antiviral therapy in patients with chronic hepatitis C after renal transplantation
por: Li, Guanghui, et al.
Publicado: (2020)

Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents
por: Cholankeril, George, et al.
Publicado: (2017)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Direct Acting Antivirals in Hepatitis C-Infected Kidney Transplant Recipients: Associations with Long-term Graft Failure and Patient Mortality
por: Goetsch, Michael R., et al.
Publicado: (2020)

Erratum to “Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients”
por: Calogero, Armando, et al.
Publicado: (2019)

Seroprevalence of Hepatitis E among Iranian Renal Transplant Recipients
por: Rostamzadeh Khameneh, Zakieh, et al.
Publicado: (2011)

Hypozincemia in Chronic Hepatitis C Is Improved with Viral Clearance by Direct-acting Antiviral Agents
por: Shirahashi, Ryosaku, et al.
Publicado: (2021)

The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection
por: Dawood, Reham M, et al.
Publicado: (2022)

Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
por: John, Jason J., et al.
Publicado: (2021)

Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents
por: Estefan, Sergio, et al.
Publicado: (2021)

Hepatitis C-related membranoproliferative glomerulonephritis in the era of direct antiviral agents
por: Abdelhamid, Walid Ahmed Ragab, et al.
Publicado: (2021)

HCV-infected Renal Transplant Recipients: Our Experience before the Availability of New Antiviral Drugs
por: Fernandes, A. R., et al.
Publicado: (2017)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021)

Tomoelastography for Longitudinal Monitoring of Viscoelasticity Changes in the Liver and in Renal Allografts after Direct-Acting Antiviral Treatment in 15 Kidney Transplant Recipients with Chronic HCV Infection
por: Marticorena Garcia, Stephan R., et al.
Publicado: (2021)

A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil
por: Silva, Isabella Patrícia Lima, et al.
Publicado: (2021)

Safety and mortality outcomes for direct oral anticoagulants in renal transplant recipients
por: Firth, Christine, et al.
Publicado: (2023)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Antivirals for COVID-19 in Solid Organ Transplant Recipients
por: Laracy, Justin C., et al.
Publicado: (2020)

Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agents
por: Yan, Taotao, et al.
Publicado: (2019)

Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China
por: Zhang, Jian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ct84em8b1ecgvth9148c2k8c73